KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Novavax (NVAX) Enterprise Value: 2009-2025

Historic Enterprise Value for Novavax (NVAX) over the last 17 years, with Sep 2025 value amounting to $645.3 million.

  • Novavax's Enterprise Value fell 42.00% to $645.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.6 billion, marking a year-over-year decrease of 64.42%. This contributed to the annual value of $364.8 million for FY2024, which is 21508.71% up from last year.
  • Latest data reveals that Novavax reported Enterprise Value of $645.3 million as of Q3 2025, which was up 58.13% from $408.1 million recorded in Q2 2025.
  • Novavax's 5-year Enterprise Value high stood at $13.7 billion for Q2 2021, and its period low was -$529.9 million during Q4 2022.
  • Its 3-year average for Enterprise Value is $353.5 million, with a median of $299.5 million in 2025.
  • Per our database at Business Quant, Novavax's Enterprise Value slumped by 105.70% in 2022 and then spiked by 21,508.71% in 2024.
  • Novavax's Enterprise Value (Quarterly) stood at $9.3 billion in 2021, then plummeted by 105.70% to -$529.9 million in 2022, then spiked by 100.32% to $1.7 million in 2023, then surged by 21,508.71% to $364.8 million in 2024, then crashed by 42.00% to $645.3 million in 2025.
  • Its last three reported values are $645.3 million in Q3 2025, $408.1 million for Q2 2025, and $299.5 million during Q1 2025.